AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Seekingalpha

Published November 12, 2026

U.S. funding to support studies into psychedelic drug ibogaine in PTSD - Seeking Alpha

Read the full story at Seekingalpha

HHS commits up to $4.9M in funds over five years to advance studies into the psychedelic drug ibogaine in PTSD and other mental health conditions.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
LSD